Jun 6 |
Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?
|
Jun 6 |
Insider Sale: Chief Development Officer William Guyer Sells 10,000 Shares of Corcept ...
|
Jun 3 |
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
|
May 31 |
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?
|
May 31 |
Insider Sale: Chief Development Officer William Guyer Sells 30,000 Shares of Corcept ...
|
May 29 |
Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
|
May 28 |
Corcept climbs as late-stage trial for Cushing’s syndrome therapy succeeds
|
May 28 |
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
|
May 13 |
3 High Insider Ownership US Growth Companies With Earnings Growth Up To 70%
|
May 13 |
Pipeline Moves: Phase III completion for Corcept’s relaorilant
|